The global market for Endometriosis Drugs is projected to reach US$2.6 billion by 2022, driven by large-scale efforts towards awareness campaigns, and growing spending on treatment of gynecological disorders amid societal changes, worldwide.
Endometriosis is one of the most common, yet little-known disease affecting women, where uterine tissue grows outside the uterus and causes debilitating pain, infertility, painful intercourse, depression, and amenorrhea. Endometriosis treatment is mainly dominated by hormonal therapies, such as progestin treatment or contraceptive pills that reduce menstrual cycles. Abbvie's Lupron and oral contraceptive pills (from Bayer among others) have traditionally been used to treat endometriosis and its symptoms. However, these drugs were not designed for endometriosis in the first place, and represent a temporary solution before surgery is considered. Extensive research is now ongoing to decipher the exact causes of endometriosis, and develop drugs which offer long-term cure for the condition instead of stop-gap solutions.
Prevailing trends in the endometriosis drugs market include growing use of oral contraceptive pills (OCPs), comprising female hormones like progestin and estrogen, and soaring popularity of intrauterine devices (IUDs) in treatment procedures. IUDs are being favored owing to rising awareness about adverse side effects of other therapeutic options. In addition, myths are being dispelled regarding the disease and alternative methods are being readily accepted. Non-invasive diagnostics, including next-generation MRIs, are forecast to become major tools for the diagnosis of endometriosis, although laparoscopy, an invasive surgery, still remains the gold standard for performing disease diagnosis. Genetic and biomolecular diagnostic tests are also being trailed.
Future prospects remain promising for the endometriosis drugs market, with full-scale efforts being made in research, and novel treatment emerging in the field of surgical as well as pharmaceutical treatment. New prospects including Elagolix and Relugolix (TAK-385), both of which are in Phase III study, along with other pipeline drugs such as Proellex, BAY 98-7196, and ASP-1707 are expected to play pivotal role in growth and expansion of the market upon their commercial release. Further, mass campaigns such as Worldwide Endometriosis Day being implemented to bring awareness about the condition among women and general population, will also have a strong impact on present and future growth.
The United States represents the largest market worldwide. Asia-Pacific ranks as the fastest growing market with a CAGR of 3.4% over the analysis period, led by large population and unmet therapeutic needs for endometriosis, increasing awareness about the condition, and increasing healthcare spending among the growing base of affluent, middle class population.
Major players in the market include AbbVie Inc., Astellas Pharma Inc., AstraZeneca Plc, Bayer AG, Debiopharm Group, Evotec AG, Kissei Pharmaceutical Co. Ltd., Neurocrine Biosciences Inc., ObsEva SA, Pfizer Inc., Repros Therapeutics Inc., Roivant Sciences GmbH, Takeda Pharmaceutical Company Limited, and ValiRx plc among others.